4.6 Article

Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy

期刊

PLOS ONE
卷 7, 期 11, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0048839

关键词

-

资金

  1. Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR
  2. U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) [U01-AI069907]
  3. Merck Sharp Dohme
  4. Gilead
  5. Bristol-Myers Squibb
  6. Boehringer Ingelheim
  7. Roche
  8. Pfizer
  9. GlaxoSmithKline
  10. Janssen-Cilag
  11. Australian Government Department of Health and Ageing
  12. Johnson Johnson
  13. CSL Ltd.
  14. Merck
  15. BMS
  16. Abbott
  17. ViiV

向作者/读者索取更多资源

Background: Life expectancy has increased for newly diagnosed HIV patients since the inception of combination antiretroviral treatment (cART), but there remains a need to better understand the characteristics of long-term survival in HIV-positive patients. We examined long-term survival in HIV-positive patients receiving cART in the Australian HIV Observational Database (AHOD), to describe changes in mortality compared to the general population and to develop longer-term survival models. Methods: Data were examined from 2,675 HIV-positive participants in AHOD who started cART. Standardised mortality ratios (SMR) were calculated by age, sex and calendar year across prognostic characteristics using Australian Bureau of Statistics national data as reference. SMRs were examined by years of duration of cART by CD4 and similarly by viral load. Survival was analysed using Cox-proportional hazards and parametric survival models. Results: The overall SMR for all-cause mortality was 3.5 (95% CI: 3.0-4.0). SMRs by CD4 count were 8.6 (95% CI: 7.2-10.2) for CD4<350 cells/mu l; 2.1 (95% CI: 1.5-2.9) for CD4 = 350-499 cells/mu l; and 1.5 (95% CI: 1.1-2.0) for CD4 >= 500 cells/mu l. SMRs for patients with CD4 counts<350 cells/mu l were much higher than for patients with higher CD4 counts across all durations of cART. SMRs for patients with viral loads greater than 400 copies/ml were much higher across all durations of cART. Multivariate models demonstrated improved survival associated with increased recent CD4, reduced recent viral load, younger patients, absence of HBVsAg-positive ever, year of HIV diagnosis and incidence of ADI. Parametric models showed a fairly constant mortality risk by year of cART up to 15 years of treatment. Conclusion: Observed mortality remained fairly constant by duration of cART and was modelled accurately by accepted prognostic factors. These rates did not vary much by duration of treatment. Changes in mortality with age were similar to those in the Australian general population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据